SPY001 vs Zotemtegrast
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: α4β7 integrin · full Ulcerative Colitis pipeline
SPY001
Developed by Spyre Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07012395 (registry estimate)
No aligned efficacy figure on record for this race.
Zotemtegrast
Developed by Eli Lilly
NCT05291689 · Phase 2 · completed
This was a single-group, open-label study with 39 participants overall and no placebo or active comparator. The primary clinical/histopathology endpoint was reported as a mean change, but without a comparator there was no formal between-group comparison to establish efficacy.
Next expected readout: May 2027 · NCT07186101 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% (missed)
Result source: NCT05611671
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | SPY001 | Zotemtegrast |
|---|---|---|
| Clinical remission (induction) | —Not reported | 31.9% vs 24.3%+7.6 vs placeboNCT056116712 other results
|
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Clinical response (induction) | —Not reported | 62.3% vs 54.3%+8 vs placeboNCT056116712 other results
|
| Endoscopic improvement (induction) | —Not reported | —Not reported |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- SPY001
- —Not reported
- Zotemtegrast
- 31.9% vs 24.3%+7.6 vs placeboNCT05611671
2 other results
- 23.9% vs 24.3% NCT05611671
- 17.1% vs 24.3% NCT05611671
Clinical remission (maintenance)
- SPY001
- —Not reported
- Zotemtegrast
- —Not reported
Clinical response (induction)
- SPY001
- —Not reported
- Zotemtegrast
- 62.3% vs 54.3%+8 vs placeboNCT05611671
2 other results
- 53.5% vs 54.3% NCT05611671
- 57.1% vs 54.3% NCT05611671
Endoscopic improvement (induction)
- SPY001
- —Not reported
- Zotemtegrast
- —Not reported
Corticosteroid-free remission (maintenance)
- SPY001
- —Not reported
- Zotemtegrast
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SPY001: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. SPY001: 0 of 4 rows · Zotemtegrast: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Zotemtegrast |
|---|---|
| Dropout rate | 75%MORF-057 (Exploratory Cohort) NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 show 4 more results51.4%MORF-057 (Main Cohort) NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 5.8%200 mg BID NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 4.2%100 mg BID NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 4.3%100 mg QD-M NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Discontinued due to AEs | 75%MORF-057 (Exploratory Cohort) NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 show 4 more results8.6%MORF-057 (Main Cohort) NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 1.4%200 mg BID NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 1.4%100 mg BID NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 0%100 mg QD-M NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Serious AEs | 0%MORF-057 (Exploratory Cohort) NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 show 4 more results0%MORF-057 (Main Cohort) NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 1.4%200 mg BID NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 4.2%100 mg BID NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 0%100 mg QD-M NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Most frequent reported AEs | colitis ulcerative 100% anaemia 25% erythema 25% NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 show 4 more resultscolitis ulcerative 20% anaemia 8.6% acne 5.7% NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 200 mg BID headache 7.1% (placebo 2.9%) nasopharyngitis 4.3% (placebo 5.8%) anaemia 2.9% (placebo 5.8%) NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 100 mg BID headache 5.6% (placebo 2.9%) nasopharyngitis 4.2% (placebo 5.8%) anaemia 2.8% (placebo 5.8%) NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 100 mg QD-M anaemia 4.3% (placebo 5.8%) headache 2.9% (placebo 2.9%) nasopharyngitis 0% (placebo 5.8%) NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Zotemtegrast
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SPY001's landscape · Zotemtegrast's landscape